PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service.

Biologicals. 1998 Jun;26(2):101-4. Unique Identifier : AIDSLINE MED/99030780
Schottstedt V; Tuma W; Bunger G; Lefevre H; Red Cross Blood Transfusion Service North-Rhine Westfalia,; Germany.

Abstract: We adapted the PCR method to screen up to 3000 blood donations per day for hepatitis B, hepatitis C and HIV-1 virus contamination. Up to 600 aliquots (average 418 donations) are pooled by using an automatic sample processor with disposable tips (validated to avoid contamination) taken from blood donations which are serologically negative and free for clinical usage according to federal regulations. In the case of a positive PCR pool result the viraemic donation is identified by two additional PCR pools testing steps with smaller pool sizes. All of the steps are supported by electronic data processing. After virus concentration by ultracentrifugation, and in the case of HCV and HIV-1 an additional reverse transcription step, PCR amplifications are performed. PCRs are done for each virus in two genomic regions. Laser-induced detection after PAGE and computer-analysis are used to identify the amplification products. Using this validated methodology routine we have checked 428 896 donations up to the end of August 1996. During this survey we found at least 24 viruses-containing donations which were negative in corresponding serological tests and would have been transfused (2 HBV-, 22 HCV-, 0 HIV-1 -containing donations). It seems possible for large transfusion centres to shorten the diagnostic window periods with our PCR-methodology with acceptable costs (15 DM per donation for all three viruses including logistics, developments and investments). Copyright 1998 The International Association of Biological Standardization

Keywords: JOURNAL ARTICLE AIDS Serodiagnosis Blood Donors Blood Transfusion/*ADVERSE EFFECTS Costs and Cost Analysis Evaluation Studies False Negative Reactions Germany Hepatitis B/DIAGNOSIS/TRANSMISSION Hepatitis B Virus/*GENETICS/*ISOLATION & PURIF Hepatitis C/DIAGNOSIS/TRANSMISSION Hepatitis C-Like Viruses/*GENETICS/*ISOLATION & PURIF Human HIV Infections/DIAGNOSIS/TRANSMISSION HIV-1/*GENETICS/*ISOLATION & PURIF Mass Screening Polymerase Chain Reaction/ECONOMICS/*METHODS/STATISTICS & NUMER DATA Sensitivity and Specificity Serologic Tests Viremia/DIAGNOSIS Virology/ECONOMICS/METHODS/STATISTICS & NUMER DATA
990228
A9920930

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .